CapForce (OPGN) Q2 2025 earnings summary

Executive summary

• Transitioned from precision medicine to financial services and technology, forming CapForce International Holdings Ltd. to offer listing sponsorship and consultancy services and develop digital investment banking platforms.

• Legacy subsidiaries Curetis and Ares Genetics were deconsolidated after insolvency proceedings; assets sold to third parties.

• Control shifted to AEI Capital Ltd. after a series of preferred stock transactions and board changes; company now operates virtually.

Financial highlights

• Revenue for Q2 2025 was $4.0 million, entirely from listing sponsorship services; no product or lab service revenue due to business repositioning.

• Net income for Q2 2025 was $3.5 million, compared to a net loss of $1.6 million in Q2 2024.

• Operating expenses decreased 62% year-over-year for Q2 2025, reflecting the scale-down of legacy operations.

• Cash and cash equivalents were $0.8 million as of June 30, 2025, down from $1.3 million at year-end 2024.

Outlook and guidance

• Anticipates funding operations primarily through financing arrangements with AEI Capital Ltd. until new business lines are self-sustaining.

• Plans to apply for Nasdaq relisting after meeting requirements; currently trades on OTC Markets Group Expert Market.